![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Biogen Idec Elan Pharmaceuticals |
---|---|
Information provided by: | Biogen Idec |
ClinicalTrials.gov Identifier: | NCT00030966 |
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
Condition | Intervention | Phase |
---|---|---|
Multiple Sclerosis, Relapsing-Remitting |
Drug: Natalizumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis |
Estimated Enrollment: | 1200 |
Study Start Date: | January 2002 |
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
AND
Study Director: | Michael Panzara, MD, MPH | Biogen Idec |
Principal Investigator: | Richard A Rudick, MD | The Cleveland Clinic |
Study ID Numbers: | C-1802 |
Study First Received: | February 15, 2002 |
Last Updated: | June 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00030966 |
Health Authority: | United States: Food and Drug Administration |
Multiple Sclerosis MS |
Autoimmune Diseases Multiple Sclerosis Demyelinating Diseases Interferons Interferon beta 1a Interferon-beta |
Demyelinating Autoimmune Diseases, CNS Demyelinating diseases Sclerosis Multiple Sclerosis, Relapsing-Remitting Autoimmune Diseases of the Nervous System |
Pathologic Processes Immune System Diseases Nervous System Diseases |